香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 PAK FAH YEOW INTERNATIONAL LIMITED 白 花 油 國 際 有 限 公 司 * （於百慕達註冊成立之有限公司） （股份代號：239） 二零二二年全年業績公佈 摘要 • 收入按年增加5.3%，乃歸因於醫療保健業務之銷售貢獻有所上升。 • 本集團之表現指標－基礎經常性溢利按年增加14.2%，反映醫療保健業務 表現改善。 • 報告溢利按年減少21.6%，乃由於投資物業及金融資產之未變現公平值虧 損所致，而二零二一年則錄得未變現公平值收益。 • 隨著邊境完全開放以及業務活動逐步恢復後，預計二零二三年的前景會更 明朗。 白花油國際有限公司（「本公司」）之董事會（「董事會」）謹此宣佈，本公司及其附屬 公司（「本集團」）截至二零二二年十二月三十一日止年度之綜合經審核業績，連同 ...

Financial Performance - Revenue for the first half of 2022 decreased by 0.7% to HKD 56,202,000 compared to HKD 56,606,000 in the same period of 2021[9]. - The underlying recurring profit dropped by 37.7% to HKD 7,779,000 from HKD 12,496,000 year-on-year[9]. - The reported loss for the period was HKD 2,207,000, a significant decline from a profit of HKD 10,282,000 in the previous year[10]. - The total comprehensive loss attributable to owners for the six months ended June 30, 2022, was approximately HKD 12,418,000, compared to a profit of HKD 26,279,000 in 2021[12]. - Operating profit dropped significantly to HKD 1,189, down 91.7% from HKD 14,289 year-on-year[40]. - The group incurred a loss of HKD 2,207,000 for the period, compared to a profit of HKD 10,282,000 in the same period of the previous year[55]. - The basic and diluted loss per share for the period was HKD 0.7 cents, compared to earnings of HKD 3.3 cents in the previous year[41]. - The operating performance for the first half of 2022 showed a loss of HKD 1,189,000, a significant improvement from a loss of HKD 14,289,000 in the first half of 2021[59]. Revenue Breakdown - Healthcare segment revenue slightly decreased by 0.6% to HKD 53,055,000, while property investment revenue fell by 1.9% to HKD 3,118,000[9]. - Revenue from the healthcare segment slightly decreased by 0.6% to HKD 53,055,000, down from HKD 53,399,000 in 2021, with a profit drop of 12.7% to HKD 18,571,000[13]. - Sales in the China market declined by 7.4% to HKD 35,685,000 due to lockdowns affecting logistics and sales revenue[13]. - The North American market saw significant growth of 98.8%, with sales reaching HKD 4,623,000, up from HKD 2,325,000 in 2021[13]. Investment Properties - The loss was primarily due to unrealized fair value losses on investment properties amounting to HKD 7,101,000, compared to HKD 3,458,000 in the prior year[10]. - The unrealized fair value loss of investment properties for the period was HKD 7,101,000, compared to HKD 3,458,000 in the previous year[28]. - The valuation of investment properties in Singapore remained unchanged, while the total valuation decreased by 6.7% from HKD 285,624,000 to HKD 266,482,000 due to global economic impacts[29]. - The company recorded a net revaluation loss of HKD 3,000,000 on investment properties in Hong Kong for the first half of 2022, compared to a gain of HKD 7,300,000 in the same period of 2021[70]. Equity and Assets - Total equity decreased by 4.2% to HKD 677,852,000 from HKD 707,722,000 year-on-year[5]. - The net asset value per share fell by 4.0% to HKD 2.18 from HKD 2.27[5]. - Total assets decreased to HKD 1,390,751 as of June 30, 2022, from HKD 1,437,288 as of December 31, 2021[42]. - Non-current assets decreased to HKD 604,774 from HKD 631,310 year-on-year[42]. - The group's total assets as of June 30, 2022, amounted to HKD 823,479,000, a decrease from HKD 837,749,000 as of December 31, 2021[58]. Cash Flow and Liabilities - For the six months ended June 30, 2022, the net cash generated from operating activities was HKD 8,685,000, a significant decrease from HKD 37,511,000 in the same period of 2021, representing a decline of approximately 77.8%[48]. - The total cash and cash equivalents at the end of the reporting period increased to HKD 171,240,000 from HKD 153,321,000 year-on-year, reflecting an increase of about 11.7%[48]. - The group's liabilities totaled HKD 145,627,000 as of June 30, 2022, compared to HKD 130,027,000 at the end of 2021, indicating an increase of approximately 12%[58]. - The group reported a total of HKD 9,650,000 in accounts payable as of June 30, 2022, compared to HKD 9,280,000 as of December 31, 2021[81]. Operational Challenges and Outlook - The overall economic recovery remains unclear, with global growth slowing and inflation rising impacting the company's operations[9]. - The company remains confident in its strong fundamentals despite facing unprecedented challenges in the current environment[4]. - The company plans to enhance marketing activities in North America to capture new market segments in the second half of the year[15]. - The company plans to continue focusing on cost management and exploring new market opportunities to improve financial performance[43]. - The company plans to continue exploring market expansion opportunities and new product development strategies in the upcoming periods[63]. Corporate Governance - The company has adopted the corporate governance code as per the Hong Kong Stock Exchange listing rules and has complied with the code provisions for the six months ending June 30, 2022, except for certain deviations[108]. - The roles of the Chairman and CEO are held by the same individual, with responsibilities shared among other executive directors to maintain a balance of power[109]. - The audit committee, composed of three independent non-executive directors, reviewed the interim financial report for the six months ending June 30, 2022[110].

Financial Performance - Revenue increased by 27.9% year-on-year to HKD 139,823,000, driven by higher sales in the healthcare business[10] - Reported profit improved to HKD 38,186,000 from a loss of HKD 38,356,000 in the previous year[12] - Underlying recurring profit rose by 34.9% to HKD 35,242,000, reflecting improved performance in the healthcare segment[11] - Basic earnings per share increased to HKD 12.3, while underlying recurring earnings per share rose to HKD 11.3, up 34.5%[14] - Total comprehensive income attributable to owners was approximately HKD 55,098,000 in 2021, a significant recovery from a comprehensive loss of HKD 66,980,000 in 2020[31] - Operating profit for the year was HKD 47,489,000, compared to an operating loss of HKD 33,247,000 in the previous year[196] - Profit attributable to owners of the company for the year was HKD 38,186,000, a significant recovery from a loss of HKD 38,356,000 in 2020[196] Dividends and Shareholder Returns - Total dividend per share increased by 31.3% to HKD 8.4 from HKD 6.4[14] - The company proposed a total dividend of HKD 8.4 per share for the year, up from HKD 6.4 per share in 2020[20] - The total dividend for the year is proposed at HKD 0.084 per share, consisting of an interim dividend of HKD 0.028, a final dividend of HKD 0.038, and a special dividend of HKD 0.018[125] Market and Business Strategy - The company aims to expand existing markets while exploring new market opportunities in the short to medium term[6] - The company plans to launch its healthcare product "活絡油" in mainland China in 2022, following successful registration approval[25] - The company is investing more resources in marketing activities to expand its customer base and improve regional performance[139] Healthcare Segment Performance - Healthcare segment revenue increased by 30.0% to HKD 132,998,000 in 2021 from HKD 102,323,000 in 2020[28] - Revenue from the healthcare segment rose by 30.0% to HKD 132,998,000 in 2021, driven by a 33.3% increase in sales from China[35] Investment Properties and Financial Investments - The company’s investment properties are intended to generate stable income over the long term, providing a buffer in uncertain economic conditions[9] - The investment property segment reported a slight increase in revenue of 0.6% to HKD 6,780,000 in 2021[28] - The financial assets segment reported a significant decline in income, down 84.1% to HKD 45,000 in 2021, compared to HKD 283,000 in 2020[43] - The valuation of investment properties as of December 31, 2021, was HKD 285,624,000, a slight increase of 0.2% from HKD 285,123,000 in 2020[50] Corporate Governance - The company has adopted the new corporate governance code effective from January 1, 2022, which includes policies on anti-corruption and board independence[69] - The company is committed to maintaining a transparent and responsible corporate governance framework, adhering to the corporate governance code as per the Hong Kong Stock Exchange[68] - The board consists of three executive directors, one non-executive director, and three independent non-executive directors, ensuring a balanced governance structure[70] - The company emphasizes clear communication with shareholders and adherence to the new disclosure requirements in its corporate governance report[69] Risk Management - The board is responsible for ensuring a robust and effective risk management and internal control system, recognizing that risk is inevitable but manageable to create value[104] - The risk management plan implemented during the year aims to identify, assess, manage, monitor, and report all significant risks faced by the group[105] - Regular updates on risk factors are provided to the board, with risk assessment reports covering the group's main risks and corresponding action plans[108] Employee and Training Initiatives - The group provided approximately 866.75 hours of training to employees during the year[138] - The company has established a training program for directors, ensuring continuous professional development[77] Environmental, Social, and Governance (ESG) Initiatives - The company has established a sustainable development framework integrated into various levels of the organization, including the board and the Environmental, Social, and Governance (ESG) committee[130] - The company aims to enhance its waste reduction efforts, with a target to conduct annual activities to raise employee awareness about waste reduction[133] - The group has implemented energy-saving measures, such as replacing traditional lighting with LED lights, to enhance energy efficiency and reduce greenhouse gas emissions[134] Shareholder Communication - The annual general meeting serves as a valuable opportunity for direct communication between the board and shareholders, with all resolutions passed by voting[117] - The company is committed to enhancing investor communication and has designated senior management to engage with institutional investors and analysts[118]

股份代號:239 (於百慕達 註 冊成立之有限公司) 白花油國際有限公 司＊ 2021 中期報告 本中期報告採用環保紙印製 僅供識別 ＊ | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|----------------------|-------|--------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 目 錄 | | | | | | | | | | | | | | | 頁 | | | | | 公司資料 | | 2 | | | | | | | | 摘要 | | 3 | | | | | | | | 管理層討論及分析 | | | 5 | | | | ...

股份代號:239 (於百慕達 註 冊成立之有限公司) 白花油國際有限公 司＊ s 2020 年報 僅供識別 本年報採用環保紙印製 ＊ 14 & | --- | --- | --- | --- | --- | --- | |-------|-------|-------|-------|----------|----------------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 目 錄 | | 2 | 公司資料 | | | | | | 3 | 關於我們 | | | | | | 4 | 摘要 | | | | | | | | | | | | | 5 | | 主席報告書 | | | | | 7 | | 管理層討論及分析 | | | | | 12 | | 董事會及高級管理人員 | | | | | 14 | | 企業管治報告書 | | | | | 24 | | 董事會報告書 | | | | ...

股份代號:239 (於百慕達 註 冊成立之有限公司) 白花油國際有限公 司＊ Stock Code:239 (Incorporated in Bermuda with limited liability) PAK FAH YEOW INTERNATIONAL LIMITED This Interim Report is printed on environmentally friendly paper 2020中期報告 2020INTERIM REPORT 僅供識別 本中期報告採用環保紙印製 ＊ 目 錄 頁 公司資料 2 摘要 3 管理層討論及分析 5 簡明中期財務資料的獨立核數師審閱報告 14 簡明綜合全面收益表 16 簡明綜合財務狀況表 18 簡明綜合權益變動表 20 簡明綜合現金流量表 21 簡明中期財務資料註釋 22 權益披露及其他資料 38 公司資料 二 零 二 零 年 中 期 報 告 白 花 油 國 際 有 限 公 司 2 | --- | --- | |-------------------------------------------|----------------------------- ...

Revenue and Profit Performance - Revenue increased by 4.8% year-on-year to HKD 147,761,000, driven by higher sales in the healthcare business[9] - Underlying recurring profit rose by 33.4% to HKD 35,566,000, reflecting improved performance in healthcare products, particularly in Hong Kong and Macau[9] - Reported profit decreased by 3.3% to HKD 36,046,000, primarily due to fair value losses on investment properties[10] - Basic earnings per share for reported profit fell to HKD 11.6, a decrease of 3.3%[12] - Basic recurring earnings per share increased by 32.6% to HKD 11.4[12] - Total revenue for the group in 2019 was HKD 147,800,000, representing a year-on-year increase of 4.8%[21] - The underlying recurring profit increased by 33.4% to HKD 35,600,000, primarily due to improved performance in the healthcare products business, particularly in Hong Kong and Macau[21] - The reported profit for 2019 decreased by 3.3% to HKD 36,000,000, mainly due to unrealized fair value losses on investment properties[21] - The healthcare segment's revenue for 2019 was HKD 136,611,000, up 4.3% from HKD 130,962,000 in 2018[31] - Revenue from Hong Kong increased by 19.4% to HKD 79,968,000, while revenue from mainland China decreased by 44.8% to HKD 11,393,000[36] Dividends and Shareholder Equity - Total dividend per share increased by 4.3% to HKD 10.80[12] - The company proposed a final dividend of HKD 0.038 per share, maintaining the same level as the previous year, resulting in a total dividend of HKD 0.108 per share for 2019[22] - Shareholders' equity rose by 0.5% to HKD 760,117,000[12] - The total dividend for the year is proposed at HKD 10.8 per share, consisting of an interim dividend of HKD 0.07 and a final dividend of HKD 0.038[123] Market Strategy and Growth - The company aims to expand existing markets while seeking opportunities in new markets for its healthcare products[5] - Long-term growth strategy includes investing in brand building and market share despite an uncertain outlook for 2020[11] - The company aims to maintain growth while continuing to invest in brand building and market share as part of its long-term growth strategy[28] Investment Properties and Financial Management - The company’s investment properties are intended to generate stable income over the long term, providing a buffer in uncertain economic conditions[8] - The fair value loss on investment properties at year-end 2019 amounted to HKD 1,400,000, compared to a gain of HKD 11,500,000 in 2018[23] - The group's investment properties were valued at HKD 346,432,000 as of December 31, 2019, a slight increase of 0.8% from HKD 343,731,000 in 2018[50] - The debt-to-equity ratio was 2.6% as of December 31, 2019, down from 2.9% in 2018, with total bank borrowings amounting to HKD 19,492,000[51] - The current ratio improved to 3.31 times as of December 31, 2019, compared to 2.81 times in 2018, indicating sufficient liquidity to meet short-term obligations[51] Risk Management and Corporate Governance - The board is responsible for ensuring compliance with legal and regulatory requirements[73] - The company has adopted all code provisions of the Corporate Governance Code as set out in the Listing Rules, demonstrating commitment to transparency and accountability[66] - The company’s governance structure includes a mix of professionals with expertise in accounting, finance, and law, contributing to informed decision-making[67] - The board is responsible for ensuring a robust risk management and internal control system, with the audit committee assisting in this responsibility[99] - The risk management plan aims to ensure all significant risks are properly identified, assessed, managed, monitored, and reported to the audit committee and the board[100] Employee and Training Initiatives - The total number of employees was 90 as of December 31, 2019, a slight decrease from 91 in 2018[56] - The company provided around 334 hours of training to employees during the year, emphasizing its commitment to workforce development[134] Environmental, Social, and Governance (ESG) Commitments - The company has established an Environmental, Social, and Governance (ESG) committee to oversee its environmental policies and performance[128] - The group has implemented various energy-saving measures, including replacing traditional lighting with LED lights, to reduce carbon emissions[131] - The company has designed and implemented a self-assessment and evaluation plan for all suppliers to manage environmental and social risks in the supply chain[140] Audit and Financial Reporting - The independent auditor's report was issued on March 26, 2020, by the auditing firm Zhongzheng CPA (Hong Kong) Limited[194] - The company’s financial statements for the year ended December 31, 2019, were audited and deemed to fairly reflect the financial position and performance of the group[180] - The auditors aim to obtain reasonable assurance that the financial statements are free from material misstatement due to fraud or error[190]

Financial Performance - Revenue increased by 65.6% to HKD 74,771,000 compared to HKD 45,150,000 in the same period last year[7] - Basic recurring profit surged by 2,813.1% to HKD 23,538,000 from HKD 808,000 year-on-year[12] - Reported profit rose by 52.9% to HKD 21,331,000, driven primarily by improved performance in the healthcare segment[15] - Earnings per share for reported profit increased by 51.1% to HKD 6.8 from HKD 4.5 in the previous year[15] - Total comprehensive income attributable to owners was approximately HKD 35,822,000, up from HKD 29,872,000 in the previous year[17] - Operating profit for the period was HKD 26,993,000, up 76.5% from HKD 15,291,000 in the previous year[49] - Profit attributable to owners of the company was HKD 21,331,000, representing a 53.1% increase from HKD 13,949,000 in 2018[49] - Basic and diluted earnings per share increased to HKD 6.84 from HKD 4.48, reflecting a growth of 52.8%[51] - Total comprehensive income for the period was HKD 35,822,000, compared to HKD 29,872,000 in the same period last year, marking a 19.8% increase[51] Segment Performance - The healthcare segment's revenue grew by 71.1% to HKD 69,459,000, while property investment revenue increased by 13.0% to HKD 4,948,000[13] - The company reported a significant increase in segment profit to HKD 31,292,000, up 471.1% from HKD 5,479,000 in the previous year[19] - The healthcare segment reported a profit of HKD 31,292,000, while property investment and financial investment segments reported profits of HKD 715,000 and HKD 1,632,000 respectively[65] Revenue Sources - Revenue from Hong Kong surged by 346.3% to HKD 53,977,000, while Macau's revenue decreased by 29.0% to HKD 5,191,000[19] - For the six months ended June 30, 2019, total external sales revenue was HKD 74,771,000, with healthcare contributing HKD 69,459,000, property investment HKD 4,948,000, and financial investment HKD 364,000[65] Expenses and Costs - Total operating expenses decreased by 29.4% to HKD 12,772,000, reflecting reduced sales and promotional expenses[31] - Financial costs decreased by 5.4% to HKD 525,000, with an interest coverage ratio rising to 55.6 from 3.9 in 2018[33] - Tax expenses increased to HKD 5,137,000 from HKD 787,000, mainly due to higher taxable operating profits from Hong Kong subsidiaries[34] Assets and Liabilities - Total assets as of June 30, 2019, amounted to HKD 941,727,000, while total liabilities were HKD 169,771,000, leading to a net asset position of HKD 771,956,000[68] - The current ratio as of June 30, 2019, was 2.76 times, slightly down from 2.81 times on December 31, 2018, indicating sufficient liquidity to meet short-term obligations[39] - The company's total liabilities decreased to HKD 14,264,000 from HKD 24,651,000, reflecting a reduction of approximately 42.3%[87] Shareholder Information - The company declared an interim dividend of HKD 5,454,000, compared to HKD 13,868,000 in the previous year[58] - The company declared a second interim dividend of HKD 0.021 per share, an increase from HKD 0.0175 per share in the previous year[120] - As of June 30, 2019, the total shares held by Mr. Yan Wei Shan amounted to 94,912,322, representing approximately 30.46% of the company's issued shares[112] - Mr. Yan Fu Wei held a total of 72,974,799 shares, which is about 23.42% of the company's issued shares[114] - Brooke Capital Limited is a significant shareholder with 34,283,500 shares, accounting for 11.00% of the company's issued shares[117] Corporate Governance - The company has adopted the corporate governance code as per the listing rules, ensuring compliance with the guidelines during the six months ending June 30, 2019[124] - The audit committee consists of three independent non-executive directors and meets at least twice a year to review the interim financial information[127] - The interim financial information for the six months ending June 30, 2019, has been reviewed by the company's auditor, confirming no amendments were necessary[127] Strategic Focus - The company plans to focus more on local demand and consumption due to anticipated decreases in tourist arrivals[7] - The market strategy will shift focus towards local demand and consumption due to anticipated declines in tourist numbers affecting sales performance[44] - The group has terminated the distribution rights in mainland China and appointed a new distributor effective July 1, 2019, aiming to enhance brand awareness and profitability[44] Investment and Valuation - The company recorded a net revaluation surplus of HKD 3,700,000 from investment properties in Hong Kong, down from HKD 11,960,000 in 2018[85] - The company experienced a net revaluation loss of HKD 7,275,000 from investment properties in the UK, compared to a revaluation gain of HKD 1,403,000 in the previous year[85] - The company's valuation estimates are based on multiple factors, including operating cash flows and industry trends[108]

Financial Performance - Revenue decreased by 20.9% year-on-year to HKD 141,043,000, attributed to a decline in sales contribution from the healthcare business[11] - Reported profit fell by 63.7% to HKD 37,280,000, primarily due to a decrease in fair value gains from investment properties[12] - Underlying recurring profit dropped by 58.0% to HKD 26,670,000, reflecting weak performance in the healthcare product business, especially in Hong Kong and mainland China[11] - Earnings per share for reported profit decreased by 63.5% to HKD 12.0, while underlying recurring earnings per share fell by 57.8% to HKD 8.6[11] - Total dividends per share were reduced by 30.3% to HKD 10.35[11] - The total comprehensive income attributable to the company's owners was approximately HKD 52,914,000, down from HKD 154,419,000 in 2017[31] - The company proposed a final dividend of HKD 0.038 per share, down from HKD 0.056 per share in 2017, resulting in a total dividend of HKD 0.1035 per share for 2018[19] Market Strategy - The company aims to expand existing markets for current products while seeking opportunities to enter new markets in the short to medium term[10] - Long-term strategy includes extending market reach to mainstream distribution channels and local communities in overseas markets[10] - The company plans to continue focusing on growth and enhancing brand awareness in various operational regions despite increasing market challenges[25] - The North American market is expected to see continued sales growth in 2019 following the appointment of a new exclusive distributor[35] - Southeast Asia maintained stable growth, with new retail stores being added and new market strategies implemented to strengthen the brand[35] Corporate Governance - The company has maintained a strong corporate governance structure, adhering to the corporate governance code as per the Hong Kong Stock Exchange's listing rules[67] - The chairman and CEO roles are held by the same individual, with responsibilities shared among executive directors to ensure a balance of power[67] - The board includes one non-executive director and three independent non-executive directors, providing diverse independent perspectives[67] - The company is committed to continuous review and enhancement of its corporate governance practices[67] - The company emphasizes transparency and accountability to shareholders in its governance approach[67] Risk Management - The board is responsible for ensuring a robust risk management and internal control system, with the audit committee assisting in this responsibility[109] - The company has implemented a risk management plan to identify, assess, manage, and monitor all significant risks faced by the group[110] - The internal audit company has been engaged to assist the board in reviewing the internal control system, with a three-year internal audit plan approved by the board[117] - The board believes that effective risk management mechanisms and internal control systems were implemented for the fiscal year ended December 31, 2018[119] Environmental, Social, and Governance (ESG) - The company established an Environmental, Social, and Governance (ESG) committee to oversee its environmental policies and performance[138] - The company emphasizes effective raw material management to mitigate risks associated with resource scarcity and protect endangered plants[139] - The company has implemented guidelines for waste management to ensure compliance with relevant laws and minimize environmental impact[140] - The group made charitable donations totaling HKD 79,000 during the year, with employees raising an additional HKD 170,000 for charity[134] Employee Management - Employee turnover rate decreased from 13.0% in 2017 to 9.9% in 2018[143] - Training hours for employees increased from 287 hours in 2017 to 467 hours in 2018[144] - The group has established a policy to ensure fair and competitive compensation for employees[143] Supplier and Customer Relations - The top five suppliers accounted for over 70% of the group's total revenue during the reporting year[148] - The top five customers accounted for 70.7% of the group's total revenue in 2018, with the largest customer contributing 18.2%[178] - The main suppliers have established over 15 years of business relationships with the group, with procurement from the top five suppliers accounting for approximately 75% of total purchases[150] Financial Position - The debt-to-equity ratio as of December 31, 2018, was 2.9%, down from 3.6% in 2017[50] - Total bank borrowings amounted to HKD 21,893,000 as of December 31, 2018, compared to HKD 26,660,000 in 2017[50] - The current ratio as of December 31, 2018, was 2.81 times, down from 2.98 times in 2017[50] - The valuation of investment properties as of December 31, 2018, was HKD 343,731,000, a slight increase of 0.8% from HKD 340,961,000 in 2017[48] Audit and Compliance - The independent auditor, Crowe Horwath (HK) CPA Limited, has audited the consolidated financial statements for the year ended December 31, 2018[183] - The audit committee reviewed the financial statements for the year ending December 31, 2017, and the six months ending June 30, 2018[88] - The company has established a whistleblowing policy to address concerns regarding financial reporting and internal controls[88]